These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2893022)

  • 1. Mazindol in Duchenne muscular dystrophy.
    Coakley JH; Edwards RH; Moorcraft J; Hipkin LJ; Smith CS
    Lancet; 1988 Jan; 1(8578):184. PubMed ID: 2893022
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of mazindol on growth hormone secretion in boys with Duchenne muscular dystrophy.
    Coakley JH; Moorcraft J; Hipkin LJ; Smith CS; Griffiths RD; Edwards RH
    J Neurol Neurosurg Psychiatry; 1988 Dec; 51(12):1551-7. PubMed ID: 3221222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mazindol and growth hormone inhibition in Duchenne muscular dystrophy.
    Zatz M; Vainzof M; Rapaport D; da Rocha JM; Pavanello Rde C; Betti RT
    Am J Med Genet; 1987 Aug; 27(4):993-5. PubMed ID: 3321999
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of mazindol on growth hormone levels in patients with Duchenne muscular dystrophy.
    Zatz M; Rapaport D; Vainzof M; Pavanello Rde C; Rocha JM; Betti RT; Otto PA
    Am J Med Genet; 1988 Dec; 31(4):821-33. PubMed ID: 3239574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Duchenne muscular dystrophy with growth hormone inhibitors.
    Zatz M; Betti RT; Frota-Pessoa O
    Am J Med Genet; 1986 Jul; 24(3):549-66. PubMed ID: 3524231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, double-blind trial of mazindol in Duchenne dystrophy.
    Griggs RC; Moxley RT; Mendell JR; Fenichel GM; Brooke MH; Miller PJ; Mandel S; Florence J; Schierbecker J; Kaiser KK
    Muscle Nerve; 1990 Dec; 13(12):1169-73. PubMed ID: 2266990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nocturnal rhythm of growth hormone in Duchenne patients: effect of different doses of mazindol and/or cyproheptadine.
    Zatz M; Rapaport D; Pavanello RC; Rocha JM; Vainzof M; Nicolau W
    Am J Med Genet; 1989 Aug; 33(4):457-67. PubMed ID: 2596504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth hormone inhibition causes increased selenium levels in Duchenne muscular dystrophy: a possible new approach to therapy.
    Collipp PJ; Kelemen J; Chen SY; Castro-Magana M; Angulo M; Derenoncourt A
    J Med Genet; 1984 Aug; 21(4):254-6. PubMed ID: 6492089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of a growth hormone inhibitor on the course of Duchenne's myopathy].
    Serratrice G; Desnuelle C
    Presse Med; 1988 Nov; 17(41):2201. PubMed ID: 2974583
    [No Abstract]   [Full Text] [Related]  

  • 10. [A therapeutic trial of mazindol versus placebo in Duchenne muscular dystrophy. A one-year follow-up study of 14 children].
    Desnuelle C; Serratrice G; N'guyen VK; Richelme C; Pinsard N
    Arch Fr Pediatr; 1989 Dec; 46(10):759-65. PubMed ID: 2697199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Overweight as a therapeutic problem. Experience with the appetite depressant Mazindol].
    Linke H
    Med Welt; 1976 Oct; 27(42):2021-5. PubMed ID: 792620
    [No Abstract]   [Full Text] [Related]  

  • 12. AN 448 Sandoz (Mazindol) in the treatment of obesity.
    Wallace AG
    Med J Aust; 1976 Mar; 1(11):343-5. PubMed ID: 775265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical evaluation of Teronac (mazindol) in the treatment of obesity in children. Part II. Anorectic properties and side effects (author's transl)].
    Gołebiowska M; Chlebna-Sokół D; Kobierska I; Konopińska A; Małek M; Mastalska A; Zwaigzne-Raczyńska J
    Przegl Lek; 1981; 38(3):355-8. PubMed ID: 7017827
    [No Abstract]   [Full Text] [Related]  

  • 14. [Mazindol (Teronac) in the treatment of predominant by food-dependent obesity].
    Husmann F
    Med Welt; 1976 Oct; 27(40):1904-8. PubMed ID: 790077
    [No Abstract]   [Full Text] [Related]  

  • 15. Double-blind evaluation of mazindol in refractory obesity.
    Smith RG; Innes JA; Munro JF
    Br Med J; 1975 Aug; 3(5978):284. PubMed ID: 1097046
    [No Abstract]   [Full Text] [Related]  

  • 16. Mazindol in the control of micturition.
    Woodhouse CR; Tiptaft RC
    Br J Urol; 1983 Dec; 55(6):636-8. PubMed ID: 6360295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind clinical evaluation of mazindol (42-548) in obese diabetics.
    Bandisode MS; Boshell BR
    Curr Ther Res Clin Exp; 1975 Dec; 18(6):816-24. PubMed ID: 813947
    [No Abstract]   [Full Text] [Related]  

  • 18. Letter: Drugs in obesity.
    Jackson WP; Vinik AI
    S Afr Med J; 1975 May; 49(20):803. PubMed ID: 1098170
    [No Abstract]   [Full Text] [Related]  

  • 19. Maziniol in the treatment of obesity.
    Sedgwick JP
    Practitioner; 1975 Mar; 214(1281):418-20. PubMed ID: 1096123
    [No Abstract]   [Full Text] [Related]  

  • 20. [Mazindol: a new anorectic drug].
    Siani V
    Clin Ter; 1978 Jan; 84(1):100-1. PubMed ID: 630811
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.